ThesisKrystal Biotech: the setup is constructive — VYJUVEK quarterly revenue performance and patient enrollment metrics (total patients on therapy, new patient starts…
growth - The stock attracts growth-oriented investors focused on rare disease biotechnology with commercial validation.
Rising interest rates create moderate headwinds through two channels: (1) higher discount rates compress the present value of future cash…
Watch on earnings: VYJUVEK quarterly net revenue and year-over-year growth rates, Total active DEB patients on therapy and quarterly patient additions, Average revenue per patient and pricing stability amid payer negotiations.
One Sentence Summary:
The bull case is simple: analysts see revenue climbing from $507M to $662M as vyjuvek quarterly revenue performance and patient enrollment metrics (total patients on therapy, new patient starts.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
